909 related articles for article (PubMed ID: 17626365)
1. Sensitivity of Leishmania braziliensis promastigotes to meglumine antimoniate (glucantime) is higher than that of other Leishmania species and correlates with response to therapy in American tegumentary leishmaniasis.
Azeredo-Coutinho RB; Mendonça SC; Callahan H; Portal AC; Max G
J Parasitol; 2007 Jun; 93(3):688-93. PubMed ID: 17626365
[TBL] [Abstract][Full Text] [Related]
2. In vitro sensitivity of Leishmania (Viannia) braziliensis and Leishmania (Leishmania) amazonensis Brazilian isolates to meglumine antimoniate and amphotericin B.
Zauli-Nascimento RC; Miguel DC; Yokoyama-Yasunaka JK; Pereira LI; Pelli de Oliveira MA; Ribeiro-Dias F; Dorta ML; Uliana SR
Trop Med Int Health; 2010 Jan; 15(1):68-76. PubMed ID: 19874570
[TBL] [Abstract][Full Text] [Related]
3. Sensitivity to Glucantime of Leishmania viannia isolated from patients prior to treatment.
Robledo SM; Valencia AZ; Saravia NG
J Parasitol; 1999 Apr; 85(2):360-6. PubMed ID: 10219320
[TBL] [Abstract][Full Text] [Related]
4. Responses of Leishmania (Viannia) braziliensis cutaneous infection to N-methylglucamine antimoniate in the rhesus monkey (Macaca mulatta) model.
Teva A; Porrozzi R; Oliveira-Neto MP; Grimaldi GJ
J Parasitol; 2005 Aug; 91(4):976-8. PubMed ID: 17089782
[TBL] [Abstract][Full Text] [Related]
5. Resistance to antimony and treatment failure in human Leishmania (Viannia) infection.
Rojas R; Valderrama L; Valderrama M; Varona MX; Ouellette M; Saravia NG
J Infect Dis; 2006 May; 193(10):1375-83. PubMed ID: 16619185
[TBL] [Abstract][Full Text] [Related]
6. Influence of Leishmania (Viannia) species on the response to antimonial treatment in patients with American tegumentary leishmaniasis.
Arevalo J; Ramirez L; Adaui V; Zimic M; Tulliano G; Miranda-Verástegui C; Lazo M; Loayza-Muro R; De Doncker S; Maurer A; Chappuis F; Dujardin JC; Llanos-Cuentas A
J Infect Dis; 2007 Jun; 195(12):1846-51. PubMed ID: 17492601
[TBL] [Abstract][Full Text] [Related]
7. American cutaneous leishmaniasis caused by Leishmania (Viannia) braziliensis resistant to meglumine antimoniate, but with good response to pentamidine: a case report.
Pimentel MI; Baptista C; Rubin EF; Vasconcellos Ede C; Lyra MR; Salgueiro Mde M; Saheki MN; Rosalino CM; Madeira Mde F; Silva AF; Confort EM; Schubach Ade O
Rev Soc Bras Med Trop; 2011; 44(2):254-6. PubMed ID: 21552747
[TBL] [Abstract][Full Text] [Related]
8. Clinical and Parasitological Features of Patients with American Cutaneous Leishmaniasis that Did Not Respond to Treatment with Meglumine Antimoniate.
Perez-Franco JE; Cruz-Barrera ML; Robayo ML; Lopez MC; Daza CD; Bedoya A; Mariño ML; Saavedra CH; Echeverry MC
PLoS Negl Trop Dis; 2016 May; 10(5):e0004739. PubMed ID: 27243811
[TBL] [Abstract][Full Text] [Related]
9. Genotypic profiles of Leishmania (Viannia) braziliensis strains from cutaneous leishmaniasis patients and their relationship with the response to meglumine antimoniate treatment: a pilot study.
Gagini T; de Oliveira Schubach A; de Fatima Madeira M; Maria Valete-Rosalino C; Fernandes Pimentel MI; da Silva Pacheco R
Parasite; 2017; 24():34. PubMed ID: 28959938
[TBL] [Abstract][Full Text] [Related]
10. Antibody response in patients with cutaneous leishmaniasis infected by Leishmania (Viannia) braziliensis or Leishmania (Viannia) guyanensis in Brazil.
Romero GA; de la Glória Orge Orge M; de Farias Guerra MV; Paes MG; de Oliveira Macêdo V; de Carvalho EM
Acta Trop; 2005 Jan; 93(1):49-56. PubMed ID: 15589797
[TBL] [Abstract][Full Text] [Related]
11. Molecular epidemiology and in vitro evidence suggest that Leishmania braziliensis strain helps determine antimony response among American tegumenary leishmaniasis patients.
Silva SC; Guimarães LH; Silva JA; Magalhães V; Medina L; Queiroz A; Machado PRL; Schriefer A
Acta Trop; 2018 Feb; 178():34-39. PubMed ID: 29042262
[TBL] [Abstract][Full Text] [Related]
12. In vitro sensitivity of paired Leishmania (Viannia) braziliensis samples isolated before meglumine antimoniate treatment and after treatment failure or reactivation of cutaneous leishmaniasis.
Baptista C; Miranda Lde F; Madeira Mde F; Leon LL; Conceição-Silva F; Schubach Ade O
Dis Markers; 2015; 2015():943236. PubMed ID: 25802480
[TBL] [Abstract][Full Text] [Related]
13. Comparison of meglumine antimoniate and pentamidine for peruvian cutaneous leishmaniasis.
Andersen EM; Cruz-Saldarriaga M; Llanos-Cuentas A; Luz-Cjuno M; Echevarria J; Miranda-Verastegui C; Colina O; Berman JD
Am J Trop Med Hyg; 2005 Feb; 72(2):133-7. PubMed ID: 15741547
[TBL] [Abstract][Full Text] [Related]
14. A randomized clinical trial comparing oral azithromycin and meglumine antimoniate for the treatment of American cutaneous leishmaniasis caused by Leishmania (Viannia) braziliensis.
Krolewiecki AJ; Romero HD; Cajal SP; Abraham D; Mimori T; Matsumoto T; Juarez M; Taranto NJ
Am J Trop Med Hyg; 2007 Oct; 77(4):640-6. PubMed ID: 17978064
[TBL] [Abstract][Full Text] [Related]
15. Targeted gene expression profiling in Leishmania braziliensis and Leishmania guyanensis parasites isolated from Brazilian patients with different antimonial treatment outcomes.
Torres DC; Adaui V; Ribeiro-Alves M; Romero GA; Arévalo J; Cupolillo E; Dujardin JC
Infect Genet Evol; 2010 Aug; 10(6):727-33. PubMed ID: 20478409
[TBL] [Abstract][Full Text] [Related]
16. Leishmania infantum: stage-specific activity of pentavalent antimony related with the assay conditions.
Carrió J; de Colmenares M; Riera C; Gállego M; Arboix M; Portús M
Exp Parasitol; 2000 Jul; 95(3):209-14. PubMed ID: 10964649
[TBL] [Abstract][Full Text] [Related]
17. Development of Leishmania (Viannia) panamensis lesions and relationship of numbers of amastigotes to lesion area on antimony-treated and untreated hamsters.
Hanson WL; Chapman WL; Waits VB; Lovelace JK
J Parasitol; 1991 Oct; 77(5):780-3. PubMed ID: 1919929
[TBL] [Abstract][Full Text] [Related]
18. A trial of immunotherapy against Leishmania amazonensis infection in vitro and in vivo with Z-100, a polysaccharide obtained from Mycobacterium tuberculosis, alone or combined with meglumine antimoniate.
Barroso PA; Marco JD; Calvopina M; Kato H; Korenaga M; Hashiguchi Y
J Antimicrob Chemother; 2007 Jun; 59(6):1123-9. PubMed ID: 17439977
[TBL] [Abstract][Full Text] [Related]
19. Canine visceral leishmaniasis: comparison of in vitro leishmanicidal activity of marbofloxacin, meglumine antimoniate and sodium stibogluconate.
Vouldoukis I; Rougier S; Dugas B; Pino P; Mazier D; Woehrlé F
Vet Parasitol; 2006 Jan; 135(2):137-46. PubMed ID: 16242844
[TBL] [Abstract][Full Text] [Related]
20. American tegumentary leishmaniasis: Is antimonial treatment outcome related to parasite drug susceptibility?
Yardley V; Ortuno N; Llanos-Cuentas A; Chappuis F; Doncker SD; Ramirez L; Croft S; Arevalo J; Adaui V; Bermudez H; Decuypere S; Dujardin JC
J Infect Dis; 2006 Oct; 194(8):1168-75. PubMed ID: 16991093
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
